Skip to content
Bored Studies
RecruitingPhase 4

A Study to Evaluate the Effect of KarXT on Urological Safety

Bristol-Myers Squibb · NCT07221877

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
60
US sites recruiting
13
Study start
January 20, 2026
Record last updated
October 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

Being studied: Xanomeline/trospium chloride

Conditions: Schizophrenia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male and Female participants (age 18 to 65 years of age, with a primary diagnosis of schizophrenia based on psychiatric evaluation (DSM-5) and confirmed by MINI (v 7.0.2).
  • Participants must have a PANSS total score ≤ 80 and CGI-S score ≤ 4, at screening and baseline, and a BMI ≥18 and ≤ 40 kg/m2.
  • Participants must be willing and able to discontinue all antipsychotic medications prior to the baseline visit and be willing and able to comply with protocol requirements.

Exclusion Criteria

  • Participants with newly diagnosed schizophrenia, any other DSM-5 disorder diagnosed within the past 12 months, alcohol or drug use disorder within the past 12 months, history/presence of clinically significant disease or disorder that would jeopardize participant safety or validity of study results.
  • Participants at risk for suicidal behavior, as well as individuals who are pregnant or breastfeeding, will be excluded from the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply

Recruiting US locations

  • Pillar Clinical Research- Little Rock

    Little Rock, AR 72204

    Site contact: Leslie Smith, Site 0017 · 501-350-3285

  • Clinical Innovations, Inc. dba CITrials

    Bellflower, CA 90706

    Site contact: Robert Bota, Site 0007 · 562-748-4999

  • CenExel CNS - Garden Grove

    Garden Grove, CA 92845

    Site contact: David Walling, Site 0006 · 714-799-7799

  • ATP Clinical Research

    Orange, CA 92866

    Site contact: Gustavo Alva, Site 0016 · 949-354-5353

  • Collaborative Neuroscience Research, LLC

    Torrance, CA 90504

    Site contact: Lara Shirikjian, Site 0019 · 310-523-4200

  • Health Synergy Clinical Research

    Boynton Beach, FL 33426

    Site contact: Mohammad Nisar, Site 0004 · 786-831-7303

  • Innovative Clinical Research

    Lauderhill, FL 33319

    Site contact: Rishi Kakar, Site 0003 · 786-512-4106

  • Uptown Research Institute

    Chicago, IL 60640

    Site contact: John Sonnenberg, Site 0005 · 773-968-9868

  • Pillar Clinical Research -Chicago

    Chicago, IL 60641

    Site contact: Roueen Rafeyan, Site 0010 · 312-865-6336

  • IMA Clinical Research Las Vegas

    Las Vegas, NV 89102

    Site contact: Mustafa Rawaf, Site 0013 · 702-527-7401

  • Hassman Research Institute Marlton Site

    Marlton, NJ 08053

    Site contact: Elan Cohen, Site 0002 · 267-981-8911

  • Adams Clinical Philadelphia

    Philadelphia, PA 19104

    Site contact: Cassie Blanchard, Site 0014 · 631-252-0769

  • Adams Clinical Dallas

    DeSoto, TX 75115

    Site contact: Benji Kurian, Site 0015 · 214-497-3151

Study contacts (from the official record)

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
  • First line of the email MUST contain NCT # and Site #.
All mental health studies in Arkansas →
A Study to Evaluate the Effect of KarXT on Urological Safety (NCT07221877) | Bored Studies